Wandercraft develops AI-powered, self-balancing exoskeletons and autonomous humanoid robots for rehabilitation, personal mobility, and industrial use. Its flagship rehabilitation system, Atalante X, is deployed in over 100 rehabilitation centres across four continents and helps users take more than a million steps each month. The company is commercializing Eve, a personal exoskeleton that enables wheelchair users to stand and walk, and is developing the Calvin line of humanoid robots for physically demanding tasks and caregiver support. Wandercraft refines its systems with a neural network trained on billions of steps, billions of simulations, and tens of millions of real-world steps, and holds more than 30 patents. The company says it will bring Eve to market as early as 2026, expand clinical adoption of Atalante X, and develop and deploy the Calvin-40 humanoid robot. A strategic partnership with Renault aims to scale production and positions Renault as a commercial partner and first customer for the Calvin-40. Wandercraft develops Atalante, a 12-degrees-of-freedom, self-balancing robotic exoskeleton that uses walking algorithms to restore gait for wheelchair users. The company was founded in 2012 and is Paris-based. Its product strategy focuses squarely on user mobility and rehabilitation care rather than industrial or military applications. Wandercraft partners with hospitals and healthcare providers to deploy its technology in clinical and therapeutic settings. The firm announced plans to expand Atalante’s reach into the United States following its latest financing. Financially, the company has been capital-intensive: prior to the round it had raised $30.5M to date, and it is now pursuing commercialization and development with new investor support.

Total raised

$120M

Funding rounds

2

Latest round

Series D

Latest activity

Jun 2025